Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[vestigation of molecular factors determining BRAF-inhibitor sensitivity in solid tumors].

Magyar onkologia - 17 Mar 2020

Molnár Eszter

Abstract excerpt

Targeted therapy for V600 BRAF mutant solid tumors already exists but resistance to the treatment is still a serious problem to be solved. Moreover, there are currently no approved targeted therapeutic options against non-V600 BRAF mutant tumors. Here we studied targeted therapy resistance mechanisms of V600 BRAF mutant melanoma and also explored potential alternative solutions for their treatment. In V600 BRAF...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Melanoma
Share to Mutation
Share to Protein Kinase Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Proto-Oncogene Proteins B-raf

Source

Identifiers

PMID: 32181767

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[vestigation of molecular factors determining BRAF-inhibitor sensitivity in solid tumors].PMID 32181767Read ↗

BRAF as a target for cancer therapy.Semantic proximity Read ↗

[BRAF-Mutant Solid Tumor].Semantic proximity Read ↗

Prenylation inhibition-induced cell death in melanoma: reduced sensitivity in BRAF mutant/PTEN wild-type melanoma cells.Semantic proximity Read ↗

[Resistance to BRAF inhibitors: A lesson from clinical observations].Semantic proximity Read ↗

Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells.Semantic proximity Read ↗

Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2Semantic proximity Read ↗

BRAF Targeting Across Solid Tumors: Molecular Aspects and Clinical ApplicationsSemantic proximity Read ↗

BRAF mutation and its inhibitors in sarcoma treatment.Semantic proximity Read ↗

Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2.Semantic proximity Read ↗

Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond.Semantic proximity Read ↗

Systemic review on B-RafV600E mutation as potential therapeutic target for the treatment of cancer.Semantic proximity Read ↗

Emerging BRAF Mutations in Cancer Progression and Their Possible Effects on Transcriptional Networks.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.